Beranda › Tumor Wilms
Uji klinis Tumor Wilms yang merekrut di AS
17 studi untuk Tumor Wilms merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Washington, DC7 studi
- Memphis, TN6 studi
- Atlanta, GA5 studi
- Philadelphia, PA4 studi
- Houston, TX4 studi
- Aurora, CO4 studi
- Mountain View, CA4 studi
- Minneapolis, MN4 studi
- St. Louis, MO4 studi
- Chicago, IL4 studi
- Los Angeles, CA4 studi
- New York City, NY4 studi
- Cincinnati, OH4 studi
- Boston, MA4 studi
- Greenburgh, NY4 studi
- Birmingham, AL3 studi
- Ann Arbor, MI3 studi
Berdasarkan negara bagian
- Alabama3 studi
- California5 studi
- Colorado4 studi
- Distrik Columbia7 studi
- Florida3 studi
- Georgia5 studi
- Illinois4 studi
- Massachusetts4 studi
- Michigan3 studi
- Minnesota5 studi
- Missouri4 studi
- New York6 studi
- Ohio5 studi
- Pennsylvania4 studi
- Tennessee6 studi
- Texas6 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT04616560Biomarkers of Resiliency In Childhood Cancer Surgery
Menerima pesertaStudi observasional
Usia 3 hingga 25 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06674811Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Menerima pesertaFase 2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04322318Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Menerima pesertaFase 1
Usia 1 hingga 23 · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT07172958Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT04715191Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT06625190B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Menerima pesertaFase 1
Hingga usia 21 · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT04901702A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Menerima pesertaFase 2
12 Months · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT05985161Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation
Menerima pesertaFase 2
Semua usia · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT04968990Pencil Beam Scanning in Patients With Renal Tumors
Menerima pesertaFase awal 1
Usia 0 hingga 30 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT03810651Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Menerima pesertaFase 1
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04308330Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Menerima pesertaFase 1
Usia 1 hingga 26 · Semua jenis kelamin · Diperbarui 17 Feb 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Menerima pesertaFase 1
Hingga usia 21 · Semua jenis kelamin · Diperbarui 3 Nov 2025 · NCT06198296A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Menerima pesertaFase 2
18 Months – 40 Years · Semua jenis kelamin · Diperbarui 12 Agu 2025 · NCT05135975International PPB/DICER1 Registry
Menerima pesertaStudi observasionalSukarelawan sehat diterima
0 Minutes – 100 Years · Semua jenis kelamin · Diperbarui 30 Jan 2025 · NCT03382158Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.